Valuation : NuCana plc

Market Cap 4.66M 4M 3.75M 3.43M 6.46M 445M 6.48M 44.36M 17.34M 224M 17.5M 17.12M 743M P/E 2024
-0.15x
P/E 2025 -0.2x
Enterprise Value -18.91M -16.24M -15.2M -13.92M -26.22M -1.81B -26.29M -180M -70.36M -910M -71.01M -69.48M -3.01B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day-3.92%
1 week-3.92%
Current month+11.36%
1 month+16.67%
3 months-31.63%
6 months-31.94%
Current year-59.17%
1 week 1.44
Extreme 1.44
1.55
1 month 1.21
Extreme 1.21
1.66
Current year 1.21
Extreme 1.21
3.81
1 year 1.21
Extreme 1.21
7.22
3 years 1.21
Extreme 1.21
4,051
5 years 1.21
Extreme 1.21
16,598.5
10 years 1.21
Extreme 1.21
160,000
Manager TitleAgeSince
Chief Executive Officer 58 2008-03-19
Director of Finance/CFO - 2018-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 58 2008-03-19
Director/Board Member 68 2009-12-13
Director/Board Member 72 2018-04-30
Date Insider Type Main position Quantity % Market Cap.
4/15/26 Free

Chief Operating Officer

132,600,130 416.8354%
3/18/26 Other

Head of Translational Medicine

283,984,182 892.7191%
3/18/26 Other

Founder

4,352,841,381 13,683.3844%
Change 5-day change 1-year change 3-year change Capi.($)
-3.92%-3.92%-54.63%-99.96% 6.33M
+3.31%-3.70%+61.03%+103.64% 70.64B
-0.48%+0.09%+49.82%+92.25% 66.11B
-1.03%+0.46%+8.14%-5.28% 27.98B
-2.41%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
-0.07%+0.93%+34.64%-17.45% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.50%+2.92%+43.50%+151.30% 13.69B
Average -0.68%+0.50%+47.87%+164.39% 28.79B
Weighted average by Cap. +0.29%+0.65%+56.43%+154.42%

Financials

2024 2025
Net sales - -
Net income -19M -16.31M -15.27M -13.98M -26.33M -1.81B -26.41M -181M -70.67M -914M -71.32M -69.78M -3.03B -29.35M -25.2M -23.59M -21.6M -40.69M -2.8B -40.81M -279M -109M -1.41B -110M -108M -4.68B
Net Debt -6.56M -5.63M -5.27M -4.83M -9.09M -626M -9.12M -62.42M -24.4M -316M -24.63M -24.09M -1.04B -23.58M -20.24M -18.95M -17.35M -32.68M -2.25B -32.77M -224M -87.7M -1.13B -88.51M -86.6M -3.76B
Logo NuCana plc
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Employees
11
Date Price Change Volume
26-08-27 US$1.470 -3.92% 17,399
26-08-26 US$1.530 +4.08% 13,018
26-08-25 US$1.470 0.00% 26,735
26-08-24 US$1.470 -3.29% 13,411
26-08-21 US$1.520 -0.65% 18,574

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NCNA Stock